Yarbrough Capital, LLC Crispr Therapeutics Ag Transaction History
Yarbrough Capital, LLC
- $2.58 Billion
- Q4 2024
A detailed history of Yarbrough Capital, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Yarbrough Capital, LLC holds 8,399 shares of CRSP stock, worth $423,561. This represents 0.01% of its overall portfolio holdings.
Number of Shares
8,399
Previous 8,399
-0.0%
Holding current value
$423,561
Previous $394,000
16.24%
% of portfolio
0.01%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding CRSP
# of Institutions
484Shares Held
64.1MCall Options Held
1.64MPut Options Held
1.93M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$453 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA8.74MShares$441 Million0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.81MShares$192 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$140 Million0.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.75MShares$138 Million0.07% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.93B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....